Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus, Lipid Metabolism Disorder, Fatty Acid Metabolism Disorder
About this trial
This is an interventional supportive care trial for Type 2 Diabetes Mellitus focused on measuring Omega-3 Fatty Acids, Gut Microbiota, lipid Metabolome, glycerophospholipid, Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria: Patients with type 2 diabetes have been diagnosed; Male or female aged 18-70 years; After listening to the project presentation, voluntarily participate in the study and sign an informed consent form. Exclusion Criteria: Pregnant or lactating women; Poorly controlled diabetes, i.e. HbA1c>9%; Have taken omega-3 PUFAs-related supplements in the past six months; Taking lipid-lowering drugs or other drugs that affect blood lipid metabolism; Patients with severe diabetic complications, severe hypertension, combined with diseases of the heart, brain, liver, kidney, thyroid and hematopoietic system, psychosis; Patients with severe immune system disorders; Have special diets: vegetarians, weight managers, ketogenic test takers, etc; The attending physician deems the participant unsuitable
Sites / Locations
- Lian Shui People's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
fish oil group
The placebo group
Fish oil supplement capsules contained omega-3 polyunsaturated fatty acids supplied by Royal DSM Group, the Netherlands. Each 100 grams of fish oil capsules contains mainly 36.86 grams of EPA, 17.47 grams of DHA and other types of fatty acids.
The placebo for fish oil contained corn oil (Each 100 grams of corn oil contained 45.64 grams of linoleic acid, 25.62 grams of oleic acid, 17.0 grams of palmitic acid, and other fatty acids).